Rha-PEG3-SMCC (compound 13) is a drug-linker conjugate for ADC with potent antitumor activity by using SMCC (a protein crosslinker), linked via the noncleavable ADC linker Rha-PEG3^[1].

514.57

C₂₄H₃₈N₂O₁₀

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kun Zhou, et al. Chemical Synthesis of Antibody-Hapten Conjugates Capable of Recruiting the Endogenous Antibody to Magnify the Fc Effector Immunity of Antibody for Cancer Immunotherapy. J Med Chem. 2022 Jan 13;65(1):323-332.

Rha-PEG3-SMCC (compound 13) is a drug-linker conjugate for ADC with potent antitumor activity by using SMCC (a protein crosslinker), linked via the noncleavable ADC linker Rha-PEG3^[1].

514.57

C₂₄H₃₈N₂O₁₀

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kun Zhou, et al. Chemical Synthesis of Antibody-Hapten Conjugates Capable of Recruiting the Endogenous Antibody to Magnify the Fc Effector Immunity of Antibody for Cancer Immunotherapy. J Med Chem. 2022 Jan 13;65(1):323-332.

Rha-PEG3-SMCC (compound 13) is a drug-linker conjugate for ADC with potent antitumor activity by using SMCC (a protein crosslinker), linked via the noncleavable ADC linker Rha-PEG3^[1].

514.57

C₂₄H₃₈N₂O₁₀

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kun Zhou, et al. Chemical Synthesis of Antibody-Hapten Conjugates Capable of Recruiting the Endogenous Antibody to Magnify the Fc Effector Immunity of Antibody for Cancer Immunotherapy. J Med Chem. 2022 Jan 13;65(1):323-332.